Immune reconstitution inflammatory syndrome: More answers, more questions

Samuel A. Shelburne, Martin Montes, Richard J. Hamill

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

The institution of highly active antiretroviral therapy (HAART) in HIV-infected patients restores protective immune responses against a wide variety of pathogens and dramatically decreases mortality. In a subset of patients receiving HAART, immune reconstitution is associated with a pathological inflammatory response leading to substantial short-term morbidity and even mortality. The past several years have seen marked advances in our clinical understanding of the immune reconstitution inflammatory syndrome (IRIS), but many questions remain. This article summarizes recent data on clinical risk factors for the development of IRIS. A consistent finding from multiple groups is that IRIS develops in a substantial percentage of HIV-infected patients who have an underlying opportunistic infection and receive HAART. As the use of HAART stands to markedly increase over the next several years, optimal care of patients receiving HAART will need to incorporate monitoring for and treating complications of IRIS.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume57
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Immune Reconstitution Inflammatory Syndrome
Highly Active Antiretroviral Therapy
HIV
Mortality
Opportunistic Infections
Patient Care
Morbidity

Keywords

  • HAART
  • HIV
  • Paradoxical reaction
  • Restoration

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Immune reconstitution inflammatory syndrome : More answers, more questions. / Shelburne, Samuel A.; Montes, Martin; Hamill, Richard J.

In: Journal of Antimicrobial Chemotherapy, Vol. 57, No. 2, 02.2006, p. 167-170.

Research output: Contribution to journalArticle

Shelburne, Samuel A. ; Montes, Martin ; Hamill, Richard J. / Immune reconstitution inflammatory syndrome : More answers, more questions. In: Journal of Antimicrobial Chemotherapy. 2006 ; Vol. 57, No. 2. pp. 167-170.
@article{08a0b42874be4475a30a00c3728ef3a7,
title = "Immune reconstitution inflammatory syndrome: More answers, more questions",
abstract = "The institution of highly active antiretroviral therapy (HAART) in HIV-infected patients restores protective immune responses against a wide variety of pathogens and dramatically decreases mortality. In a subset of patients receiving HAART, immune reconstitution is associated with a pathological inflammatory response leading to substantial short-term morbidity and even mortality. The past several years have seen marked advances in our clinical understanding of the immune reconstitution inflammatory syndrome (IRIS), but many questions remain. This article summarizes recent data on clinical risk factors for the development of IRIS. A consistent finding from multiple groups is that IRIS develops in a substantial percentage of HIV-infected patients who have an underlying opportunistic infection and receive HAART. As the use of HAART stands to markedly increase over the next several years, optimal care of patients receiving HAART will need to incorporate monitoring for and treating complications of IRIS.",
keywords = "HAART, HIV, Paradoxical reaction, Restoration",
author = "Shelburne, {Samuel A.} and Martin Montes and Hamill, {Richard J.}",
year = "2006",
month = "2",
doi = "10.1093/jac/dki444",
language = "English (US)",
volume = "57",
pages = "167--170",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Immune reconstitution inflammatory syndrome

T2 - More answers, more questions

AU - Shelburne, Samuel A.

AU - Montes, Martin

AU - Hamill, Richard J.

PY - 2006/2

Y1 - 2006/2

N2 - The institution of highly active antiretroviral therapy (HAART) in HIV-infected patients restores protective immune responses against a wide variety of pathogens and dramatically decreases mortality. In a subset of patients receiving HAART, immune reconstitution is associated with a pathological inflammatory response leading to substantial short-term morbidity and even mortality. The past several years have seen marked advances in our clinical understanding of the immune reconstitution inflammatory syndrome (IRIS), but many questions remain. This article summarizes recent data on clinical risk factors for the development of IRIS. A consistent finding from multiple groups is that IRIS develops in a substantial percentage of HIV-infected patients who have an underlying opportunistic infection and receive HAART. As the use of HAART stands to markedly increase over the next several years, optimal care of patients receiving HAART will need to incorporate monitoring for and treating complications of IRIS.

AB - The institution of highly active antiretroviral therapy (HAART) in HIV-infected patients restores protective immune responses against a wide variety of pathogens and dramatically decreases mortality. In a subset of patients receiving HAART, immune reconstitution is associated with a pathological inflammatory response leading to substantial short-term morbidity and even mortality. The past several years have seen marked advances in our clinical understanding of the immune reconstitution inflammatory syndrome (IRIS), but many questions remain. This article summarizes recent data on clinical risk factors for the development of IRIS. A consistent finding from multiple groups is that IRIS develops in a substantial percentage of HIV-infected patients who have an underlying opportunistic infection and receive HAART. As the use of HAART stands to markedly increase over the next several years, optimal care of patients receiving HAART will need to incorporate monitoring for and treating complications of IRIS.

KW - HAART

KW - HIV

KW - Paradoxical reaction

KW - Restoration

UR - http://www.scopus.com/inward/record.url?scp=31544479585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544479585&partnerID=8YFLogxK

U2 - 10.1093/jac/dki444

DO - 10.1093/jac/dki444

M3 - Article

C2 - 16354748

AN - SCOPUS:31544479585

VL - 57

SP - 167

EP - 170

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -